A problem arises in obesity drug trials because patients often quickly recognize whether they are taking a placebo and opt out to receive an effective treatment. The FDA has approved the MiniMed Flex, a next-generation smartphone insulin pump. The article also looks at deaths from type 5 diabetes. This information comes from MedPage Today and Bloomberg via MSN. The obesity trial dilemma affects the reliability of clinical trial results. MiniMed Flex represents an advance in technology for the treatment of diabetes.